Tactile Systems Technology Inc (TCMD) Investment Analysis:
1. Executive Summary
Tactile Systems Technology Inc., professionally known as Tactile Medical, operates as a sophisticated medical technology entity dedicated to developing and providing innovative at-home therapeutic solutions for patients with underserved chronic conditions. The primary focus of the organization is the management of lymphedema and chronic pulmonary diseases, specifically bronchiectasis and cystic fibrosis. By specializing in the transition of care from clinical and hospital environments to the residential setting, the company addresses the structural inefficiencies of traditional treatment pathways, offering physiological benefits to the patient while simultaneously reducing the financial burden on the broader healthcare ecosystem.[1, 2]
The revenue generation of Tactile Medical is fundamentally anchored in its lymphedema product line, which accounted for approximately 84% of total revenue, or $278.4 million, in the fiscal year 2025.[1, 3] This segment is driven by the sales and rentals of advanced pneumatic compression devices, including the flagship Flexitouch Plus, the Entre Plus, and the newly launched Nimbl platform.[1, 4] The remaining 16% of revenue, totaling $51.1 million in 2025, is derived from the airway clearance segment, specifically the AffloVest high-frequency chest wall oscillation (HFCWO) system.[1, 4] This segment has demonstrated significant growth velocity, with a 52% year-over-year increase, reflecting a strategic diversification into the respiratory market.[3, 4]
The company’s core products are designed to treat chronic swelling and airway obstruction through advanced mechanical mechanisms. The Flexitouch system is uniquely engineered to mimic manual lymphatic drainage (MLD), providing a programmable, sequential compression that stimulates the lymphatic system to bypass damaged or blocked areas.[5, 6] The AffloVest provides similar clinical utility for the lungs, utilizing integrated motors to create oscillation without the need for the bulky, tethered air compressors associated with legacy systems.[7, 8] These technological advantages are complemented by a service-heavy business model that assists patients and clinicians in navigating the complexities of insurance reimbursement—a critical differentiator in the durable medical equipment (DME) sector.[1, 6]
The primary customer types for Tactile Medical are patients suffering from secondary lymphedema—often resulting from cancer treatments or chronic venous insufficiency (CVI)—and respiratory patients with bronchiectasis. The company serves these end markets through a specialized commercial organization that reached a staffing model of one account manager to one product specialist by the end of 2025.[1, 9] This high-touch model ensures that clinicians can prescribe these therapies with confidence that the patient will receive the necessary training and support to achieve clinical compliance.[1, 9] Customers choose Tactile Medical over alternatives because of its extensive clinical validation, its ability to secure reimbursement from a network covering 278 million lives, and the portability of its next-generation devices.[1, 5]
2. Business Drivers & Strategic Overview
Product and Service Architecture
To understand the economic engine of Tactile Medical, an investor must examine the specific mechanics of the technology and the service layer that surrounds it. The flagship Flexitouch Plus is an advanced pneumatic compression device (APCD) that differs substantially from basic pumps. While simple pumps provide static or uniform pressure, the Flexitouch uses a proprietary "stretch and release" sequence that mimics the work of a physical therapist.[1, 5] This is particularly relevant for the head and neck indication, where Tactile holds a unique regulatory position as the only cleared device for this specific anatomy.[1, 10]
The launch of the Nimbl platform in 2025 represents a strategic move toward enhancing patient adherence.[5, 10] Medical adherence in chronic conditions is often undermined by the complexity and bulk of therapeutic devices. Nimbl addresses this by providing a lighter, more intuitive interface for both upper and lower extremity treatment, which is expected to drive higher utilization and, consequently, better clinical outcomes that can be marketed to payers.[5, 10, 11]
In the respiratory segment, the AffloVest serves the airway clearance market. The device is a fully mobile HFCWO garment. Legacy products in this space required patients to be tethered to a stationary air generator, severely limiting their quality of life.[7, 8] AffloVest’s battery-operated, integrated-motor design allows for therapy while moving, which has been the primary driver of its 66% revenue growth in the fourth quarter of 2025.[4, 9]
Strategic Moat and Competitive Advantages
Tactile Medical possesses a multifaceted economic moat that protects its pricing power and market share. This moat is constructed from four key pillars: clinical evidence, reimbursement expertise, scale of distribution, and technological integration.
- Clinical and Economic Evidence Moat: The company has invested heavily in longitudinal studies that demonstrate not only physiological improvement but also cost savings for the healthcare system. Data indicates that Flexitouch users experience a 79% reduction in cellulitis—a painful and expensive infection—and a 53% to 69% reduction in total annual healthcare costs compared to conservative therapy.[1, 5, 6] In an era of value-based care, these statistics provide a "clinical lock" on prescriptions from major cancer centers and vascular clinics.[1, 6]
- Reimbursement and Administrative Moat: The DME reimbursement process is notoriously difficult, requiring extensive documentation of "failed" conservative therapy. Tactile Medical has built a massive back-office infrastructure that handles the prior authorization and documentation requirements for thousands of unique payer plans.[1, 6] This service layer creates high switching costs for clinicians; a doctor who prescribes a competitor's pump may be forced to handle the paperwork themselves, whereas Tactile manages the end-to-end process.[1, 6]
- Regulatory and Intellectual Property: Tactile holds significant patents and FDA 510(k) clearances that provide a "time moat" against competitors.[5, 12] The head and neck clearance, in particular, remains a protected niche where no other PCD has achieved similar regulatory status.[1, 10]
- Distribution Scale: With 166 account managers and 185 specialists, Tactile’s field presence is among the largest in its niche.[1] This network allows for rapid deployment of new products and maintains the high-touch relationships with prescribing physicians that are difficult for smaller, "product-only" competitors like AIROS Medical or Bio Compression Systems to disrupt.[1, 6, 9]
Total Addressable Market (TAM) and Market Opportunity
The market opportunity for Tactile Medical is characterized by high prevalence and significant under-penetration.
| Market Segment |
Estimated Market Size (2025) |
Projected Growth (CAGR) |
Growth Drivers |
| Lymphedema Treatment |
\$0.69B - \$0.95B [13, 14] |
8.9% - 9.7% [13, 14] |
Aging population, obesity, cancer survivorship [13, 15] |
| Airway Clearance |
\$0.68B - \$0.93B [7, 8] |
5.2% - 5.3% [7, 16] |
Bronchiectasis prevalence, mobile device adoption [8, 17] |
| Pneumatic Compression |
\$0.20B+ (U.S. Only) [18] |
6.0% - 8.0% [15] |
Shift to home care, technological innovation [15, 19] |
While the current market valuations are in the hundreds of millions, the potential patient pool is much larger. In the United States alone, an estimated 3 million to 5 million people suffer from lymphedema, yet only a small fraction are currently using advanced pneumatic compression.[1, 6] The acquisition of LymphaTech in 2026 is specifically designed to address this "identification gap" by giving clinicians easy-to-use digital tools to diagnose lymphedema earlier in its progression.[2, 20, 21]
Competitive Landscape and Position
Tactile Medical is the clear leader in the U.S. advanced pneumatic compression market, but it faces competition from diverse segments of the healthcare industry.
- Direct PCD Competitors: Companies like Bio Compression Systems and Mego Afek (Lympha Press) provide similar hardware.[5, 22] However, they often lack the extensive clinical data and the direct-to-patient service model that Tactile uses to defend its 76% gross margins.[1, 6]
- General Compression Players: Essity (JOBST), Sigvaris, and Medi dominate the static compression (garments) market.[19, 22] While these products are often the first line of treatment, Tactile’s products are used when these static solutions fail, positioning Tactile as a premium, higher-efficacy provider.[14, 19]
- Respiratory Rivals: In the airway clearance space, Baxter (The Vest) is the legacy leader.[7] Tactile’s AffloVest is gaining ground by marketing the mobility and quality-of-life benefits of its integrated-motor design over Baxter's tethered systems.[7, 8]
Tactile Medical appears to be gaining ground, particularly in the airway clearance segment where it has secured prioritized placement agreements with the top 10 respiratory DMEs.[9, 23] In lymphedema, it is holding its market-leading position while attempting to expand the overall market through the LymphaTech acquisition and early-intervention strategies.[5, 24, 25]
3. Financial Performance & Valuation
2025 Financial Summary
Tactile Medical delivered a strong performance in 2025, recovering from operational headwinds encountered earlier in the year related to sales force reorganization and CRM implementation.[23]
| Metric |
Full Year 2025 |
YoY Change |
Significance |
| Total Revenue |
\$329.5M |
+12% |
Exceeded high end of guidance [3, 4] |
| Lymphedema Revenue |
\$278.4M |
+7% |
Core segment stabilization [1, 3] |
| Airway Clearance Revenue |
\$51.1M |
+52% |
High-growth diversification success [3, 4] |
| Gross Margin |
76% |
+200 bps |
Driven by manufacturing efficiency [3, 4] |
| Adjusted EBITDA |
\$44.8M |
+21% |
Strong operating leverage [3, 4, 23] |
| Net Income |
\$19.1M |
+12% |
GAAP EPS of \$0.82 [3, 4, 16] |
The fourth quarter of 2025 was particularly notable, with revenue growing 21% year-over-year to $103.6 million, indicating that the productivity improvements and the 1:1 sales model began to pay dividends toward the end of the year.[3, 4, 25]
Valuation and Financial Drivers
As of late March 2026, TCMD trades at approximately $26.13 per share.[26] The valuation reflects a company that has successfully deleveraged—retiring its $26.3 million term loan—and is now shifting its focus to capital returns and strategic M&A.[3, 4, 27]
- P/E Ratio: With a trailing EPS of $0.82, the P/E ratio is approximately 31.8x.[16, 28] While this may appear high compared to mature medical device companies, it is supported by expected earnings growth of 20% in the coming year as margins continue to expand.[28]
- Operating Leverage: A critical driver for valuation is the company's ability to grow Adjusted EBITDA faster than revenue. In 2025, revenue grew 12% while EBITDA grew 21%.[3, 4] This leverage is achieved through the maturation of the sales force and the implementation of AI tools in the back office, which reduce the incremental cost of processing new patient orders.[9, 23]
- Cash Flow and Capital Allocation: The company generated close to $43 million in operating cash flow in 2025.[4, 29] The decision to repurchase $26.5 million of stock at an average price of $12.36 (nearly 50% below current prices) demonstrates a highly disciplined approach to capital allocation that enhances per-share value.[3, 4, 30]
Valuation models, including discounted cash flow (DCF) and peer multiples, suggest a fair value for the stock in the $37.40 to $38.76 range.[31, 32, 33] This suggests the market may be underestimating the long-term durability of the lymphedema segment and the explosive growth potential of the respiratory business.
4. Risk Assessment & Macroeconomic Considerations
Execution and Operational Risks
The primary execution risk lies in the Sales Force Productivity and Retention. The high-touch 1:1 model of account managers and specialists is expensive and difficult to scale.[1, 9] In early 2025, high vacancy rates in the sales team led to a 3% decline in lymphedema sales during the first quarter.[10, 23, 24] If the company cannot maintain its specialized workforce in a tight labor market, revenue growth could stall. Furthermore, the integration of LymphaTech’s digital platform into the clinical workflow requires changing the behavior of prescribing doctors, which always carries adoption risk.[21, 34]
Regulatory and Legal Risks
- Medicare Prior Authorization (The PCD Rule): Beginning April 13, 2026, Medicare is requiring prior authorization for pneumatic compression devices under HCPCS codes E0651 and E0652.[35, 36] While management has built this into its 2026 guidance (projecting a "short-term impact"), there is a risk that the administrative delay (estimated at 5-7 days) could lead to a permanent slowdown in patient starts or an increase in order cancellations.[9, 25, 36]
- Documentation and Audit Risk: Because Tactile Medical relies on third-party clinicians to provide documentation of medical necessity, the company is vulnerable to post-payment audits.[1, 12] If Medicare or private payers determine that the documentation provided by a doctor was insufficient, Tactile could be forced to refund payments, which would damage both the balance sheet and its reputation with investors.[1, 6]
Competitive and Industry Structure Risks
The entry of Wearable Compression Technology is a long-term structural threat. Several startups are developing low-profile, active compression sleeves that do not require an external pump.[6] If these devices prove clinically non-inferior and gain reimbursement parity, Tactile’s hardware-based model could be disrupted. Additionally, the industry is witnessing a shift toward Remote Patient Monitoring (RPM).[5, 10] While Tactile is attempting to lead this with its Kylee app, failure to remain at the forefront of digital connectivity could allow a tech-first competitor to capture the clinician relationship.[2, 10, 34]
Macroeconomic Sensitivities
- Labor Inflation: As a service-oriented medical device company, Tactile is sensitive to wage increases for its clinical specialists and reimbursement experts. Operating expenses grew 20% in the fourth quarter of 2025, largely due to investments in human capital.[3, 4, 30]
- Interest Rates: While Tactile is currently debt-free, high interest rates increase the discount rate applied to its future cash flows, which can cap the P/E multiple even if fundamentals are improving.[4, 37]
- Healthcare Policy: Changes in the Affordable Care Act (ACA) or Medicare reimbursement rates for lymphedema (E0652) could significantly alter the profitability of the core business.[5, 12, 38]
Early Warning Signs and Long-Term Thesis Damage
- Early Warning Sign: A significant increase in "Sales Vacancy Rate" in the quarterly reports or a decline in "New Payer Contracts" would indicate a weakening of the commercial engine.[10, 23]
- Thesis Damage: The most damaging event would be a clinical study showing that basic pumps (E0651) are equally effective as Tactile's advanced programmable pumps (E0652), as this would destroy the justification for the \$5,000 price point and compress margins permanently.[1, 6, 14]
5. 5-Year Scenario Analysis
The following scenarios analyze the potential return for TCMD over a five-year horizon (2025–2030), assuming the share price is driven by fundamental earnings growth and market rerating.
Base Case: Disciplined Scaling (Probability: 55%)
In this scenario, Tactile Medical continues to execute its current strategy. The lymphedema business grows at 8%, while the airway clearance segment matures to a 15% growth rate. The Medicare prior authorization headwind proves temporary and is fully mitigated by the end of 2026.
- Revenue Growth: 10% CAGR, reaching \$530.7M in 2030.
- Margin Assumption: Adjusted EBITDA margins expand to 18% as the company leverages its fixed administrative costs and benefits from AI-driven back-office efficiency.
- Earnings: Net income grows to approximately \$58M.
- Share Count: Reduced to 21M through consistent opportunistic buybacks.
- Valuation: Exit multiple of 22x P/E, reflecting a high-quality, steady-growth med-tech company.
- Implied Share Price: ~$60.00.
High Case: The Digital Health Pivot (Probability: 25%)
The integration of LymphaTech and the Kylee app transforms Tactile from a hardware vendor into a "Digital Lymphatic Health" leader.[2, 21] This expands the market by identifying patients earlier and increases adherence, leading to a massive expansion of the airway clearance segment.
- Revenue Growth: 15% CAGR, reaching \$662.7M in 2030.
- Margin Assumption: Adjusted EBITDA margins reach 22% as the "software" and "service" components of the integrated solutions model begin to provide higher-margin contributions.
- Earnings: Net income reaches \$95M.
- Share Count: 20M shares.
- Valuation: Exit multiple of 30x P/E, as the company is rerated as a technology/solutions provider rather than just a DME seller.
- Implied Share Price: ~$142.00.
Low Case: Regulatory Stagnation (Probability: 20%)
Medicare and private payers implement even stricter criteria for advanced pumps, and a wearable competitor gains 10% market share. Labor costs for specialists continue to rise, preventing margin expansion.
- Revenue Growth: 3% CAGR, reaching \$382.0M in 2030.
- Margin Assumption: Adjusted EBITDA margins contract to 10% as pricing pressure from payers offsets any operational efficiencies.
- Earnings: Net income remains flat at ~$18M.
- Share Count: 23M shares (buybacks suspended to preserve cash).
- Valuation: Exit multiple of 12x P/E, reflecting a low-growth, commodity hardware company.
- Implied Share Price: ~$9.40.
5-Year Scenario Table
| Scenario |
Year 5 Revenue |
Year 5 Net Income |
Valuation Multiple (P/E) |
Implied Share Price |
5-Year Total Return |
Probability |
| High Case |
\$662.7M |
\$95M |
30.0x |
\$142.50 |
+445.3% |
25% |
| Base Case |
\$530.7M |
\$58M |
22.0x |
\$60.76 |
+132.5% |
55% |
| Low Case |
\$382.0M |
\$18M |
12.0x |
\$9.40 |
-64.0% |
20% |
| Weighted |
\$533.9M |
\$59.3M |
22.0x |
\$70.92 |
+171.4% |
100% |
ASYMMETRIC GROWTH OPPORTUNITY
6. Qualitative Scorecard
| Metric |
Score (1-10) |
Narrative Analysis |
| Management Alignment |
8 |
The CEO's 3x salary ownership requirement and a board transition to include digital expertise (Andrea Pearson) show strong alignment with long-term strategy.[12, 20, 39] |
| Revenue Quality |
9 |
Revenue is driven by medical necessity and covered by extensive payer contracts (278M lives), providing high visibility and stability.[1] |
| Market Position |
9 |
Tactile is the clear market leader in the U.S. advanced PCD market, having successfully navigated competition from larger medical conglomerates.[5, 6, 18] |
| Growth Outlook |
8 |
The airway clearance segment (+52% in 2025) provides a powerful second engine to the core lymphedema business.[3, 4, 23] |
| Financial Health |
10 |
With \$83.4M in cash and zero debt, the balance sheet is exceptionally strong for a company of this size.[3, 4, 27] |
| Business Viability |
7 |
While the business is durable, the dependence on Medicare policy (Prior Authorization) creates a central choke point that management must manage carefully.[35, 36] |
| Capital Allocation |
9 |
Management has demonstrated excellent discipline by retiring debt and buying back shares at historically low multiples.[3, 4, 30] |
| Analyst Sentiment |
9 |
Consensus remains highly positive, with a 45% projected upside and recent target increases from firms like Piper Sandler and Lake Street.[31, 32, 33] |
| Profitability |
8 |
Gross margins are near 76%, and EBITDA growth is outpacing revenue, indicating an efficient and scalable business model.[3, 4, 25] |
| Track Record |
7 |
A history of 10 consecutive quarters of EBITDA improvement demonstrates a consistent ability to create shareholder value.[23] |
| OVERALL SCORE |
8.4 / 10 |
HIGH CONVICTION Niche |
7. Conclusion & Investment Thesis
The investment thesis for Tactile Medical is centered on its evolution from a single-product manufacturer into a comprehensive platform for the management of chronic lymphedema and respiratory conditions.[2, 21] The organization has successfully cleared the operational hurdles of 2025, exiting the year with accelerated growth and a pristine balance sheet.[3, 4] The acquisition of LymphaTech and the continued expansion of the AffloVest product line provide clear catalysts for double-digit revenue growth over the next five years.[1, 23, 27]
The primary catalyst for a valuation rerating will be the company’s ability to prove that the April 2026 Medicare prior authorization rule is a manageable administrative task rather than a growth-killing barrier.[25, 35] If Tactile can maintain its 10-12% total revenue growth rate while expanding EBITDA margins toward 20%, it will likely be recognized as one of the premier growth stories in the small-cap medical technology space. The current valuation does not appear to reflect the potential of the airway clearance segment or the long-term economic benefits of the shift toward home-based therapy.
UNDERSERVED MARKET LEADER
8. Technical Analysis, Price Action & Short-Term Outlook
Tactile Systems Technology (TCMD) is currently trading around $26.13, which is below its 200-day moving average of $28.27, suggesting a short-term bearish trend.[26, 40] The RSI of 42.9 indicates that the stock is neither overbought nor oversold, but rather in a period of consolidation following its 18% surge after the February 2025 earnings report.[3, 40] In the short term, the market is likely waiting for the first set of data points regarding the impact of the April 13, 2026 Medicare changes, making the May 2026 earnings call a critical pivot point for price action.[33, 36, 41]
CONSOLIDATING NEAR SUPPORT
- Tactile Medical posts $329.5M 2025 revenue | TCMD SEC Filing ..., https://www.stocktitan.net/sec-filings/TCMD/10-k-tactile-systems-technology-inc-files-annual-report-94fc59785d93.html
- Tactile Medical Acquires LymphaTech, Expanding Breadth and Depth of its Lymphedema Solutions Portfolio - GlobeNewswire, https://www.globenewswire.com/news-release/2026/02/17/3239725/0/en/Tactile-Medical-Acquires-LymphaTech-Expanding-Breadth-and-Depth-of-its-Lymphedema-Solutions-Portfolio.html
- Tactile Systems Technology, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results - Stock Titan, https://www.stocktitan.net/news/TCMD/tactile-systems-technology-inc-reports-fourth-quarter-and-full-year-rqk88j2pambm.html
- Tactile Systems Technology, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewswire, https://www.globenewswire.com/news-release/2026/02/17/3239743/0/en/Tactile-Systems-Technology-Inc-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results.html
- What is Competitive Landscape of Tactile Medical Company? - Matrix BCG, https://matrixbcg.com/blogs/competitors/tactilemedical
- What is Competitive Landscape of Tactile Medical Company? - Porter's Five Forces, https://portersfiveforce.com/blogs/competitors/tactilemedical
- Airway Clearance System Market Size & Growth Trends, 2032, https://www.persistencemarketresearch.com/market-research/airway-clearance-system-market.asp
- Air Way Clearance Market Size, Top Share, Demand | Industry Report, 2034, https://straitsresearch.com/report/air-way-clearance-market
- Tactile Systems Technology, Inc. (TCMD) Q4 2025 Earnings Call ..., https://seekingalpha.com/article/4871207-tactile-systems-technology-inc-tcmd-q4-2025-earnings-call-transcript
- What is Growth Strategy and Future Prospects of Tactile Medical Company? - Matrix BCG, https://matrixbcg.com/blogs/growth-strategy/tactilemedical
- 2024 Corporate Responsibility and Sustainability Report - Tactile Medical, https://tactilemedical.com/wp-content/uploads/2025/11/2024-Corporate-Responsibility-and-Sustainability-Report_704044-001-Rev-A.pdf
- TCMD SEC Filings - Tactile Systems 10-K, 10-Q, 8-K Forms - Stock Titan, https://www.stocktitan.net/sec-filings/TCMD/
- Lymphedema Treatment Market Size & Share Outlook to 2031 - Mordor Intelligence, https://www.mordorintelligence.com/industry-reports/lymphedema-treatment-market
- Lymphedema Treatment Market Share & Opportunities 2025-2032, https://www.coherentmarketinsights.com/industry-reports/lymphedema-treatment-market
- Projected 7.7% CAGR in Pneumatic Compression Devices for Lymphedem Market 2025-2032: Trend Analysis and Competitive Tracking Insights · Apiary, https://pneumaticcompressiondevicesforlymphedemmarketsharemarkettrend.docs.apiary.io/
- Tactile Systems Technology Inc Stock Price Today | NASDAQ: TCMD Live - Investing.com, https://www.investing.com/equities/tactile-systems-technology-inc
- Bronchiectasis Market Size to Reach USD 766.7 Million by 2035, Impelled by Advancements in Diagnostic Improvements and the Escalating Incidence of Bronchiectasis. - BioSpace, https://www.biospace.com/press-releases/bronchiectasis-market-size-to-reach-usd-766-7-million-by-2035-impelled-by-advancements-in-diagnostic-improvements-and-the-escalating-incidence-of-bronchiectasis
- Pneumatic compression therapy market share in the US: recent trends, https://www.medicaldevice-network.com/data-insights/market-share-analysis-pneumatic-compression-therapy-the-us/
- Compression Therapy Market Size, Trends & Forecast 2026–2035, https://www.gminsights.com/industry-analysis/compression-therapy-market
- Investors - Tactile Systems Technology, Inc., https://investors.tactilemedical.com/
- Tactile Medical acquires LymphaTech for $6.8 million - Investing.com, https://www.investing.com/news/company-news/tactile-medical-acquires-lymphatech-for-68-million-93CH-4509697
- BSN Medical (Germany) and medi GmbH & Co. KG (Germany) are Leading Players in the Compression Therapy Market - MarketsandMarkets, https://www.marketsandmarkets.com/ResearchInsight/compression-therapy-market.asp
- Tactile Systems Technology, Inc. (TCMD) Stock Price, Market Cap, Segmented Revenue & Earnings - Datainsightsmarket.com, https://www.datainsightsmarket.com/companies/TCMD
- Tactile Systems Technology, Inc. Reports First Quarter 2025 Financial Results - Investors, https://investors.tactilemedical.com/news-releases/news-release-details/tactile-systems-technology-inc-reports-first-quarter-2025
- Tactile Medical expects 8%-11% revenue growth in 2026 while expanding integrated lymphedema solutions (NASDAQ:TCMD) | Seeking Alpha, https://seekingalpha.com/news/4553033-tactile-medical-expects-8-percentminus-11-percent-revenue-growth-in-2026-while-expanding
- Tactile Systems Technology Stock Price Forecast. Should You Buy TCMD? - StockInvest.us, https://stockinvest.us/stock/TCMD
- Tactile Systems (NASDAQ: TCMD) delivers 2025 growth and acquires LymphaTech, https://www.stocktitan.net/sec-filings/TCMD/8-k-tactile-systems-technology-inc-reports-material-event-64c54bebecd1.html
- Tactile Systems Technology (TCMD) Earnings Date and Reports 2026 - MarketBeat, https://www.marketbeat.com/stocks/NASDAQ/TCMD/earnings/
- Tactile Systems Technology Q4 2025 Earnings Report - MarketBeat, https://www.marketbeat.com/earnings/reports/2026-2-17-tactile-systems-technology-inc-stock/
- Tactile Systems Technology, Inc. Reports Strong Q4 and Full Year 2025 Financial Results with Revenue Growth and Strategic Acquisition, https://www.quiverquant.com/news/Tactile+Systems+Technology,+Inc.+Reports+Strong+Q4+and+Full+Year+2025+Financial+Results+with+Revenue+Growth+and+Strategic+Acquisition
- Tactile Systems (TCMD) Stock Forecast & Price Target - Investing.com, https://www.investing.com/equities/tactile-systems-technology-inc-consensus-estimates
- TCMD / Tactile Systems Technology, Inc. (NasdaqGM) - Forecast, Price Target, Estimates, Predictions - Fintel, https://fintel.io/sfo/us/tcmd
- Tactile Systems Technology (TCMD) Stock Forecast and Price Target 2026 - MarketBeat, https://www.marketbeat.com/stocks/NASDAQ/TCMD/forecast/
- In brief: Tactile Systems buys LymphaTech, AAH shows impact, Numotion settles lawsuit, https://www.hmenews.com/article/in-brief-tactile-systems-buys-lymphatech-aah-shows-impact-numotion-settles-lawsuit
- Pneumatic Compression Devices (PCD) to Prior Authorization Coming Soon - Article Detail - JD DME - Noridian, https://med.noridianmedicare.com/web/jddme/article-detail/-/view/2230715/pneumatic-compression-devices-pcd-to-prior-authorization-coming-soon
- Medicare Requires Prior Authorization for Pumps Starting 4/13/26, https://lymphedemaadvocacygroup.org/medicare-requires-prior-authorization-for-pumps-starting-4-13-26/
- TCMD: Lymphedema Momentum And Q4 Execution Will Support Multi Year Upside, https://simplywall.st/community/narratives/us/healthcare/nasdaq-tcmd/tactile-systems-technology/dxke77al-tcmd-market-leadership-and-coverage-momentum-will-drive-expansion-into-underserved-patients/updates/21-analysts-have-lifted-the-consolidated-price-target-for-tacti
- Medicare Program; Updates to the Master List of Items Potentially Subject to Face to Face Encounter and Written Order Prior to Delivery and/or Prior Authorization Requirements - Federal Register, https://www.federalregister.gov/documents/2026/01/13/2026-00487/medicare-program-updates-to-the-master-list-of-items-potentially-subject-to-face-to-face-encounter
- [ARS] TACTILE SYSTEMS TECHNOLOGY INC SEC Filing | TCMD ..., https://www.stocktitan.net/sec-filings/TCMD/ars-tactile-systems-technology-inc-sec-filing-da5a4eb9e0df.html
- TCMD Technical Analysis, RSI and Moving Averages - Investing.com, https://www.investing.com/equities/tactile-systems-technology-inc-technical
- Tactile Systems (TCMD) Earnings: Latest Report, Earnings Call & Financials - Public Investing, https://public.com/stocks/tcmd/earnings